Drug treatment of epilepsy in the century of the ILAE: The second 50 years, 1959–2009
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Summary: The drug therapy of epilepsy evolved enormously in this 50 year period. Advances in therapeutics included the incorporation of pharmacokinetics into clinical practice, enormous advances in neurochemistry, a trend to antiepileptic drug monotherapy, better drug assessment, better understanding of therapeutic outcomes, and the recognition of the large epilepsy treatment gap in many countries. An unprecedented range of new drugs was introduced in this period. Before 1989, these included carbamazepine, valproate, ethosuximide, and the benzodiazepines. Since 1989, 13 more new drugs have been licensed and marketed and there are others in the pipeline. The International League Against Epilepsy and its leading figures have played an important role in these developments. In this period, too, there has been a rapid expansion in research and development within the pharmaceutical industry and a rise in the value of the antiepileptic drug market. In parallel, governmental regulation of pharmaceuticals has greatly increased. To what extent the overall prognosis of epilepsy has improved as a result of these activities is an interesting and perplexing question.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marson, A. G., Al-Kharusi, A. M., Alwaidh, M., Appleton, R., Baker, G. A., Chadwick, D. W., Cramp, C., Cockerell, O. C., Cooper, P. N., Doughty, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60460-7 · Cited by 976
Mbuba, C. K., Ngugi, A. K., Newton, C. R., & Carter, J. A. (2008) · Epilepsia · doi:10.1111/j.1528-1167.2008.01693.x · Cited by 407 · cited 1×
“How successful this will be is as yet not known, but a recent review of treatment gap figures suggests indeed that it may be lessening (Mbuba et al., 2008).”
BackgroundRzany, B., Correia, O., Kelly, J. P., Naldi, L., Auquier, A., & Stern, R. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05418-x · Cited by 348 · cited 1×
“Nevertheless, serious rash was reported to occur at a rate of about 0.3% even in 1999 (Rzany et al., 1999).”
InfluentialTreatment of status epilepticus with diazepam (Valium)
GASTAUT, H., NAQUET, R., POIRÉ, R., & TASSINARI, C. A. (1965) · Epilepsia · doi:10.1111/j.1528-1157.1965.tb03786.x · Cited by 182
Cited by
Löscher, W. (2011) · Seizure · doi:10.1016/j.seizure.2011.01.003 · Cited by 932
Modern antiepileptic drug development has failed to deliver: Ways out of the current dilemma
Löscher, W., & Schmidt, D. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03024.x · Cited by 590
Löscher, W., & Brandt, C. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003046 · Cited by 414
Löscher, W. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2222-z · Cited by 367
Veroniki, A. A., Cogo, E., Rios, P., Straus, S. E., Finkelstein, Y., Kealey, R., Reynen, E., Soobiah, C., Thavorn, K., Hutton, B., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0845-1 · Cited by 339
Metadata
- Authors
- Shorvon, S. D.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2009-03
- Volume
- 50
- Issue
- s3
- Pages
- 93-130
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2146599781
- Cited by
- 140
- References
- 5
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug treatment of epilepsy in the century of the ILAE: The second 50 years, 1959–2009. https://app.cochat.ai/papers/10.1111/j.1528-1167.2009.02042.x
- The paper
- Shorvon, S. D. (2009). Drug treatment of epilepsy in the century of the ILAE: The second 50 years, 1959–2009. Epilepsia. https://doi.org/10.1111/j.1528-1167.2009.02042.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.